Fisher Asset Management LLC increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 33.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 182,997 shares of the company’s stock after purchasing an additional 45,813 shares during the quarter. Fisher Asset Management LLC’s holdings in Ionis Pharmaceuticals were worth $8,171,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Alyeska Investment Group L.P. boosted its holdings in Ionis Pharmaceuticals by 199.7% during the second quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock worth $112,427,000 after buying an additional 944,766 shares in the last quarter. Bank of America Corp DE acquired a new position in Ionis Pharmaceuticals during the second quarter worth about $62,718,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Ionis Pharmaceuticals during the second quarter worth about $54,253,000. TimesSquare Capital Management LLC purchased a new position in Ionis Pharmaceuticals in the second quarter valued at about $48,690,000. Finally, Bank of New York Mellon Corp purchased a new position in Ionis Pharmaceuticals in the second quarter valued at about $43,011,000. Institutional investors and hedge funds own 93.86% of the company’s stock.
Insider Activity at Ionis Pharmaceuticals
In other Ionis Pharmaceuticals news, Director Michael Hayden acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was acquired at an average cost of $29.64 per share, with a total value of $148,200.00. Following the purchase, the director directly owned 27,000 shares in the company, valued at approximately $800,280. This trade represents a 22.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares of the company’s stock, valued at $775,490.94. This represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by corporate insiders.
Analyst Ratings Changes
IONS has been the subject of a number of research reports. Raymond James Financial reiterated an “outperform” rating and set a $54.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, November 9th. Oppenheimer decreased their price target on Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 10th. Guggenheim lowered their price target on Ionis Pharmaceuticals from $89.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, September 15th. Canaccord Genuity Group dropped their price objective on Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, September 8th. Finally, Needham & Company LLC reduced their price objective on Ionis Pharmaceuticals from $86.00 to $54.00 and set a “buy” rating for the company in a report on Monday, November 9th. Nineteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $75.71.
Check Out Our Latest Stock Analysis on Ionis Pharmaceuticals
Trending Headlines about Ionis Pharmaceuticals
These are some of the IONS headlines that stood out recently:
- Positive Sentiment: Director Michael Hayden purchased 5,000 shares for $148,200, increasing his Ionis holdings by 22.7%—an insider buy that may signal confidence in the company. SEC filing
- Negative Sentiment: Ionis reportedly cut its full-year TRYNGOLZA sales outlook by roughly half after third-quarter sales reached just $9.3 million. The sales shortfall prompted investor-law-firm investigations, creating additional legal and reputational overhang. Investor investigation notice Wolf Popper investigation
- Negative Sentiment: Several firms—including Morgan Stanley, Needham, HC Wainwright, Oppenheimer and Goldman Sachs—cut price expectations; a separate analyst downgrade was associated with a sharp recent decline in the shares. Artisan Partners also said its small-cap growth strategy exited Ionis following sequential Phase 3 setbacks. Morgan Stanley price target Artisan Partners exit
Ionis Pharmaceuticals Stock Performance
NASDAQ:IONS opened at $29.06 on Monday. The company has a current ratio of 5.43, a quick ratio of 5.36 and a debt-to-equity ratio of 3.42. The firm has a 50-day moving average price of $43.65 and a two-hundred day moving average price of $64.57. Ionis Pharmaceuticals, Inc. has a twelve month low of $27.25 and a twelve month high of $86.74. The company has a market capitalization of $4.84 billion, a P/E ratio of -8.75 and a beta of 0.43.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company had revenue of $242.72 million during the quarter, compared to analysts’ expectations of $178.17 million. During the same quarter in the previous year, the business posted ($0.80) earnings per share. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. As a group, research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Read More
- Five stocks we like better than Ionis Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
